PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Healthy Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01652638
• Other study ID #: HEPBLA0312SC-I
• Secondary ID: Version 01 15/03
• Status: Not yet recruiting
• Phase: Phase 1
• First received: July 26, 2012
• Last updated: August 10, 2012
• Start date: February 2013
• Est. completion date: April 2013

Study information

• Verified date: August 2012
• Source: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
• Contact: Alexandre Frederico, physician
• Phone: +55 19 3871-6399
• Email: alexandre[@]lalclinica.com.br
• Is FDA regulated: No
• Health authority: Brazil: National Health Surveillance Agency
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by Laboratory Blau Farmacêutica S/A, compared to the product of Heparin Sodium ® company APP Pharmaceuticals, through the determination of activity of the following markers:

• Anti-FXa;

• Anti-FIIA.

Description:

The pharmacodynamic profile of the drug will be assessed through:

• Reason for Anti-FXa activity / Anti-FIIA;

• TFPI activity.

The aPTT activity marker will be evaluated as an exploratory objective.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Confirm the voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;

2. Being male, aged between 18 and 55 years old and clinically healthy;

3. BMI = 18.5 and = 30.

Exclusion Criteria:

1. Participation in clinical trials in the 12 months preceding the survey;

2. Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;

3. acute illness in the period up to 07 days before the beginning of the study;

4. determining Chronic administration of medications, such as hypertension, diabetes or any other that requires continued use of any drug;

5. Hemoglobin <13 g / dL;

6. Continuous use of oral anticoagulants, platelet inhibitors or anti-inflammatory;

7. Use of medications that interact with heparin (see Section 7.8.1);

8. history of gastrointestinal bleeding, deep vein thrombosis or pulmonary embolism;

9. History of coagulopathy and bleeding diathesis;

10. Presence of bruises on physical examination.

11. Changes in skin or subcutaneous tissue of the place where the injection is made (eg liposuction in the abdomen).

12. absolute platelet count below 100 x 109 / L;

13. A history of acute haemorrhage in the last 30 days;

14. history of sensitivity to biological products derived from mammalian albumin or any component of the formulation;

a) history of allergy or major disease Steven Johnson; p) History of present use or there are at least 12 months of tobacco; q) current or previous history (less than 12 months) of illicit drug use;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Heparin
Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.

Locations

Country	Name	City	State
Brazil	LAL Clínica Pesquisa e Desenvolvimento Ltda.	Valinhos

Sponsors (1)

Lead Sponsor	Collaborator
L.A.L Clinica Pesquisa e Desenvolvimento Ltda.

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacodynamic of activity of markers: Anti-Fxa and Anti-FIIA.	Blood sample	0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.	Yes
Secondary	Pharmacodynamic of the ratio between the activity Anti-FXa/Anti-FIIa and the activity of TFPI.	Blood sample	TFPI: 0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.	Yes